# ASCO-like Scorecard Generation Results (Single LLM Approach)

Date Generated: 2025-05-20 11:57:21

---

## Scorecard 1: Enzalutamide Versus Placebo After Chemotherapy in Metastatic Adenocarcinoma of Prostate

**Scenario Hint:** A trial of a novel hormone therapy against placebo in advanced prostate cancer after chemotherapy. Focus on Overall Survival. Hypothesize a plausible positive outcome with some expected toxicities and potential for bonus points typical for such a scenario.

| Measure                   | Result/Score                                                                                                                     |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score**| ((1 – 0.75) * 100 * 1) = (0.25 * 100 * 1) = **25**                                                                              |
| **Toxicity Score**        | (((18/12) – 1) * 20) = ((1.5 – 1) * 20) = (0.5 * 20) = **10** penalty applied → **-10**                                          |
| **Bonus Points**          | Tail of the Curve: +15 <br> Palliation: +5 <br> Treatment-Free Interval: +3 <br> Health-related QoL: +5                            |
| **Total Bonus Points**    | 15 + 5 + 3 + 5 = **28**                                                                                                            |
| **Net Health Benefit**    | 25 + (–10) + 28 = **43**                                                                                                           |
| **Cost**                  | Hypothesized cost: **$10,000 per month**                                                                                           |

---

## Scorecard 2: Doxorubicin + Cyclophosphamide → Paclitaxel + Trastuzumab vs Doxorubicin + Cyclophosphamide + Paclitaxel in Adjuvant HER2+ Breast Cancer

**Scenario Hint:** A trial comparing a Trastuzumab-containing regimen against a standard chemotherapy regimen in adjuvant HER2+ breast cancer. Focus on Overall Survival. Hypothesize a plausible outcome, considering the impact of a targeted therapy like Trastuzumab.

| Measure                       | Result/Score                                                                                         |
|-------------------------------|------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score**    | (1 – 0.75) × 100 × 1 = 25 → **25**                                                                     |
| **Toxicity Score**            | [(30 ÷ 25) – 1] × 20 = (1.2 – 1) × 20 = 4; with the toxicity penalty applied → **-4**                   |
| **Bonus Points**              | Tail of the Curve: 10                                                                              |
|                               | Palliation: 0                                                                                      |
|                               | Treatment-Free Interval: 0                                                                         |
|                               | Health-related QoL: 0                                                                              |
| **Total Bonus Points**        | 10 + 0 + 0 + 0 = **10**                                                                              |
| **Net Health Benefit**        | 25 + (–4) + 10 = **31**                                                                             |
| **Cost (Total Course)**       | $120,000 total course                                                                              |

---

## Scorecard 3: Ipilimumab Versus Placebo After Primary Treatment of Stage III Melanoma

**Scenario Hint:** A trial of an immunotherapy (Ipilimumab) versus placebo in the adjuvant setting for Stage III melanoma. Focus on Disease-Free Survival (DFS). Hypothesize a plausible outcome, considering typical efficacy and toxicity profiles for older immunotherapies in this setting. Toxicity might be a significant factor.

| Measure                  | Result/Score                                                                                                                                                |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – 0.75) * 100 * 1 = 0.25 * 100 = **25**                                                                                                                  |
| **Toxicity Score**        | ((20% / 5%) – 1) * 20 = ((0.20 / 0.05) – 1) * 20 = (4 – 1) * 20 = 3 * 20 = **–60**                                                                          |
| **Bonus Points**          | Tail of the Curve: **15** <br> Palliation: **0** <br> Treatment-Free Interval: **0** <br> Health-related QoL: **0**                                              |
| **Total Bonus Points**    | 15 + 0 + 0 + 0 = **15**                                                                                                                                       |
| **Net Health Benefit**    | Clinical Benefit Score + Toxicity Score + Total Bonus Points = 25 + (–60) + 15 = **–20**                                                                      |
| **Cost**                  | $150,000 total course                                                                                                                                         |

---

## Scorecard 4: Ibrutinib Versus Chlorambucil As Initial Therapy for Chronic Lymphocytic Leukemia

**Scenario Hint:** A trial comparing a newer targeted therapy (Ibrutinib) against an older chemotherapy agent (Chlorambucil) as first-line treatment for Chronic Lymphocytic Leukemia. Focus on Overall Survival. Hypothesize a plausible significant benefit for the newer agent, but also consider its unique toxicity profile.

| Measure                    | Result/Score                                                                                                                                                                             |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – HR) × 100 × 1 = (1 – 0.75) × 100 = 0.25 × 100 = **25**                                                                                                                              |
| **Toxicity Score**         | ((Experimental % / Control %) – 1) × 20 + Penalty = ((35/25 – 1) × 20) + (–5) = (0.4 × 20) – 5 = 8 – 5 = **–13**                                                                   |
| **Bonus Points**           | Tail of the Curve: **10** <br> Palliation: **5** <br> Treatment-Free Interval: **0** <br> Health-related QoL: **5**                                                                       |
| **Total Bonus Points**     | 10 + 5 + 0 + 5 = **20**                                                                                                                                                                   |
| **Net Health Benefit**     | Clinical Benefit Score + Toxicity Score + Total Bonus Points = 25 + (–13) + 20 = **32**                                                                                                  |
| **Cost**                   | **$10,000 per month**                                                                                                                                                                     |

---

